Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
VBIV

VBIV - VBI Vaccines Inc Stock Price, Fair Value and News

$0.020.00 (0.00%)
Market Closed

VBIV Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

VBIV Price Action

VBIV RSI Chart

VBIV Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

VBIV Valuation

VBIV Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

VBIV Fundamentals

VBIV Revenue

VBIV Earnings

VBIV Profitability

VBIV Investor Care

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20249.4M000
20231.4M1.8M8.1M8.7M
2022456.0K660.0K870.0K1.1M
2021947.0K905.0K714.0K631.0K
20202.3M1.8M1.5M1.1M
20193.5M3.9M4.3M2.2M
2018916.0K806.0K872.0K3.4M
2017627.0K889.0K801.0K865.0K
2016853.3K751.5K649.8K548.0K
2015000955.0K
Get all data in R, Python etc through our Historical Stock Data APIs

About VBI Vaccines Inc

VBIV
VBI Vaccines Inc., a biopharmaceutical company, develops and sells vaccines to treat immuno-oncology and infectious disease. It offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. The company also develops VBI-2601, an immunotherapeutic candidate for the treatment of chronic HBV infection; VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, which is in Phase I/IIa clinical study to treat solid tumors; VBI-1501, a prophylactic cytomegalovirus vaccine candidate that has completed Phase I clinical trial; and VBI-2501 that is in preclinical trial to treat Zika virus. In addition, it develops coronavirus vaccine candidates that include VBI-2902, VBI-2901, and VBI-2905. The company has collaboration and license agreements with Brii Biosciences Limited; GlaxoSmithKline Biologicals S.A.; and the National Research Council of Canada to develop pan-coronavirus vaccine candidate targeting COVID-19, severe acute respiratory syndrome, and Middle East respiratory syndrome. It also has a collaboration with Coalition for Epidemic Preparedness Innovations to advance vaccine candidates against Covid-19 variants. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. VBI Vaccines Inc. is based in Cambridge, Massachusetts.
 CEO
 WEBSITEvbivaccines.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES190